The recommendations for systemic anticancer therapy for stage IV NSCLC vary according to tumor histology, the patient’s performance status, and driver oncogene biomarker status, most frequently epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) translocation [4–7]. This evidence concerns the gene ALK and neoplasm.